Details

Autor(en) / Beteiligte

• YI-FRAZIER, JOYCE P.
• HILLIARD, MARISA E.
• O'DONNELL, MAEVE B.
• ZHOU, CHUAN
• ELLISOR, BRITNEY M.
• GARCIA PEREZ, SAMANTHA
• ROJAS, YULIANA
• MALIK, FAISAL
• DESALVO, DANIEL
• PIHOKER, CATHERINE
• BRADFORD, MIRANDA
• SCOTT, SAMANTHA R.
• ROSENBERG, ABBY

Titel

214-OR: Results from the Promoting Resilience in Stress Management (PRISM) Intervention—A Multisite Randomized Controlled Trial (RCT) for Teens with Type 1 Diabetes (T1D)

Ist Teil von

• Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1)

Erscheinungsjahr

2023

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Introduction: PRISM is a resilience resources intervention that teaches stress-management, goal setting, reframing, and benefit finding. We tested the efficacy of PRISM on glycemic control, diabetes distress, resilience, and quality of life. Methods: This 2-site (Seattle WA, Houston TX) 1:1 RCT of PRISM vs. usual care (UC) included teens 13-18y with T1D≥12m and diabetes distress (PAID-T) scores ≥30. A1C, distress (PAID-T), diabetes resilience (DSTAR), and diabetes quality of life (T1DAL) were assessed at baseline (BL), 6m and 12m. Regression analyses used treatment arm as the primary predictor, controlling for additional covariates (Table). Results: Teens (n=172) were 56% female, race = 73% White, 15% Black, 4% Asian, 8% other, ethnicity = 19% Hispanic, BL A1C 8.7% ± 2.0%. No differences were evident between PRISM and UC in A1C, distress, resilience, quality of life at 6 months post-baseline. However, at 12 months, participants in the PRISM arm experienced improvements in distress, resilience, and quality of life versus UC (Table). Conclusions: Resilience promotion through PRISM had multiple psychosocial benefits for a diverse sample of teens with T1D by 12-months. Integrating resilience skill-building with medical intervention may optimize diabetes outcomes. Disclosure J.P.Yi-frazier: None. C.Pihoker: None. M.Bradford: None. S.R.Scott: None. A.Rosenberg: None. M.E.Hilliard: None. M.B.O'donnell: None. C.Zhou: None. B.M.Ellisor: None. S.Garcia perez: None. Y.Rojas: None. F.Malik: None. D.Desalvo: Consultant; Dexcom, Inc., Research Support; Insulet Corporation. Funding National Institutes of Health (R01DK121224)